Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma. However, at present, durable responses are only achieved in a minority of patients. Accumulating evidence suggests that the microenvironment plays a critical role in the regulation of immunotherapeutic agents. Furthering our understanding of this relationship may help to enhance the outcomes of current immunotherapy regimens and improve the development of novel immunotherapies.
In this podcast, Patricia Pérez Galán of the IDIBAPS University Hospital Clinic, Barcelona, Spain, Stephen Ansell of the Mayo Clinic, Rochester, MN, Frederick Locke of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Francisco Hernandez-Ilizaliturri of the Roswell Park Cancer Institute, Buffalo, NY, talk on the impact and role of the tumor microenvironment on outcomes with immunotherapy in patients with non-Hodgkin lymphoma.
The post iwNHL 2021: immunotherapy and the microenvironment appeared first on VJHemOnc.
